索拉非尼联合AS_2O_3对FLT3-ITD突变白血病细胞MV-4-11的抑制作用

Inhibitory effect of sorafenib and arsenic trioxide on the FLT3ITD-mutated myelomonocytic leukemia MV-4-11 cells

目的:观察FLT3抑制剂索拉非尼(sorafenib)联合三氧化二砷(AS2O3)对FLT3-ITD突变的人类急性双表型(B、单核)髓细胞白血病MV-4-11细胞增殖、细胞周期和凋亡的作用,为该联合用药方案的临床应用提供实验依据。方法:将对数生长期的MV-4-11细胞分为4组:空白对照组(不加药),索拉非尼单药(1、10、100、1 000、5 000、10 000 nmol/L)组,AS2O3单药(0.125、0.25、0.5、1.0、2.0μmol/L)组,索拉非尼+AS2O3联合用药(10 nmol/L+1.0μmol/L)组。CCK-8法检测索拉非尼和AS2O3单用或联用对MV-4-11细胞增殖的抑制作用,流式细胞术检测MV-4-11细胞的凋亡及细胞周期。结果:索拉非尼和AS2O3单用对MV-4-11细胞的增殖均有抑制作用,且均呈浓度依赖性;两药联用对MV-4-11细胞增殖的抑制率显著高于两药的单用[(70.72±1.03)%vs(47.24±1.27)%、(20.28±0.70)%;均P<0.01),两药相互作用指数(coefficient of drug interaction,CDI)为0.696,表现出协同作用。索拉非尼可使MV-4-11细胞周期阻滞于G0/G1期,两药联用阻滞得更严重。两药联合作用于MV-4-11细胞48 h后,MV-4-11细胞早期凋亡率显著高于两药单用(89.06%vs 68.27%、78.71%;均P<0.05)。结论:索拉非尼联合AS2O3能够协同抑制MV-4-11细胞的增殖,并且比单药作用更有效地阻滞细胞周期于G0/G1,更明显地促进细胞凋亡。

Objective ： To determine the effect of the FLT3-specific inhibitor sorafenib in combination with arsenic trioxide on the proliferation, cell cycle and apoptosis of leukemia MV-4-11 cells，a biphenotypic B myelomonocytic leukemia cell line with FLT3-ITD mutations, as a model in vitro . Methods： Logarithmic phase MV-4-11 cells were cultured in the absence （control） or presence of sorafenib （1, 10, 100, 1 000, 5 000, 10 000 nmol/L）, arsenic trioxide （0.125,0.25,0.5,1.0,2.0 μmol/L）, and sorafenib （10 μmol/L） and arsenic trioxide （1.0 μmol/L） in combination, respectively, for 48 h cell proliferation was assessed by CCK-8 assay, apoptosis and cell cycle progression by flow cytometry. Results： Sorafenib and arsenic trioxide, each alone, inhibited MV-4-11 cell proliferation in a concentration dependent manner. However, the inhibitory effect was more significant （ P 〈0.01） when 10 nmol/L sorafenib and 1.0 μmol/L arsenic trioxide were used in combination （[70.72±1.03]%） than each alone （[47.24±1.27]% and [20.28±0.70]%）; the interaction coefficient for these two drugs was 0.696. Sorafenib alone resulted in cell cycle arrest in G0/G1 phase and sorafenib in combination with arsenic trioxide increased cell cycle arrest. Similarly, both sorafenib and arsenic trioxide induced MV-4-11 cell apoptosis, but they were more effective in combination than each in itself （89.06% vs 6827%, 7871%; P 〈0.05）. Conclusion： Sorafenib and arsenic trioxide, each in itself, are capable of inhibiting proliferation, blocking cycle progression, and induing apoptosis in FLT3 -mutated myeloid leukemia cells.